Clinical trials: Placebo Group
Hepatitis C, Chronic
VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo
The purpose of this study is to provide access to telaprevir for patients from the control group in the C216 study, who failed treatment for virologic reasons.
- Trial name
- NCT01054573
- Testing
- Telaprevir, pegylated interferon (Peg-IFN) alfa-2a, ribavirin (RBV)
- Where
- 48 sites in United States, Australia and 13 more
- Volunteers
- 90 people
- Sponsor
- Janssen Infectious Diseases BVBA
Essential Tremor of the Upper Limb
A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm
The purpose of this study is to determine whether a single treatment with NT 201 (botulinum toxin) is superior to placebo (no medicine) for one-sided treatment of essential tremor in the motor-dominant arm (Unilateral Period).
- Trial name
- NCT04766723
- Testing
- NT 201
- Where
- 14 sites in United States, Canada and 1 more
- Volunteers
- 78 people
- Sponsor
- Merz Pharmaceuticals GmbH
Type 2 Diabetes Mellitus
Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes
B1621007 is designed to study the safety and efficacy of PF-04937319 in patients with type 2 diabetes
- Trial name
- NCT01475461
- Testing
- PF-04937319 - 3mg, PF-04937319 - 20mg, PF-04937319 - 50mg
- Where
- 63 sites in United States, Hungary and 6 more
- Volunteers
- 345 people
- Sponsor
- Pfizer
Sarcopenia
A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study
This extension study was a 24-week off-drug follow-up of the core CBYM338E2202 (NCT ) study and the main objective was to determine the long-term durability of bimagrumab (BYM338) effect after a 6-month treatment period.
- Trial name
- NCT02468674
- Testing
- bimagrumab
- Where
- 30 sites in United States, Australia and 10 more
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals
Viruria
CMX001 in Post-transplant Patients With BK Virus Viruria
This was a randomized, double-blind, multiple-dose placebo-controlled study of oral brincidofovir (BCV) in hematopoietic stem cell transplant and renal transplant recipients with BK virus viruria.
- Trial name
- NCT00793598
- Testing
- Brincidofovir
- Where
- 15 sites in United States
- Volunteers
- 29 people
- Sponsor
- Jazz Pharmaceuticals
Low Back Pain
An Efficacy and Safety Study of Extended Release (ER) Tramadol Hydrochloride (HCl)/Acetaminophen in Participants With Chronic Low-Back Pain
The purpose of this study is to evaluate the efficacy and safety of extended release (ER) tramadol hydrochloride (HCl)/acetaminophen compared with placebo in participants with chronic (lasting a long time) low-back pain.
- Trial name
- NCT01112267
- Testing
- Tramadol HCl/acetaminophen Extended Release
- Volunteers
- 248 people
- Sponsor
- Janssen Korea, Ltd., Korea
Schizophrenia
Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia
The primary purpose of this study is to determine whether SPD489 40 mg, 100 mg, and 160 mg are effective and safe in the treatment of Negative Symptoms of Schizophrenia (NSS).
- Trial name
- NCT01738698
- Testing
- SPD489 40mg, SPD489 100mg, SPD489 160mg
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Shire
Pulmonary Disease, Chronic Obstructive
BI 113608 Administered as Tablets Twice Daily Over 4 Weeks in Patients With Chronic Obstructive Pulmonary Disease Associated With Chronic Bronchitis
The main objective of the current trial is to investigate safety, tolerability and pharmacokinetics of BI 113608 in COPD patients with symptoms of chronic bronchitis.
- Trial name
- NCT01958008
- Testing
- BI 113608 high dose b.i.d., BI 113608 low dose b.i.d.
- Where
- 6 sites in Germany
- Volunteers
- 84 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only
This study is a placebo-controlled study in patients with Type 2 Diabetes Mellitus who are either taking no diabetes medication or who are taking metformin only.
- Trial name
- NCT00518115
- Testing
- Albiglutide (GSK716155) or exenatide
- Where
- 163 sites in United States, Chile and 1 more
- Volunteers
- 361 people
- Sponsor
- GlaxoSmithKline
Acute Pain
Oral Treatment for Gynaecological Post-operative Pain With Dexketoprofen Trometamol and Tramadol Hydrochloride
This study aims to evaluate the analgesic efficacy of single and repeated doses of fixed combination of dexketoprofen trometamol (DKP) and tramadol hydrochloride (TRAM) in comparison to the single agents (and placebo for the…
- Trial name
- DAVID lap (NCT01904149)
- Testing
- Dexketoprofen-single dose, Tramadol-single dose, Dexketoprofen/Tramadol-single dose
- Where
- 28 sites in Hungary, Latvia and 6 more
- Volunteers
- 606 people
- Sponsor
- Menarini Group
Attention-Deficit Hyperactivity Disorder (ADHD)
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
A study to evaluate the efficacy and safety of dasotraline in children 6 years of age to 12 years of age with Attention-Deficit Hyperactivity Disorder (ADHD) in a simulated classroom setting.
- Trial name
- NCT02734693
- Testing
- dasotraline 4mg
- Where
- 5 sites in United States
- Volunteers
- 132 people
- Sponsor
- Sumitomo Pharma America, Inc.
Gastroesophageal Reflux
A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn
The purpose of this study is to determine whether Dexlansoprazole once daily (QD) is effective in treating patients with night heartburn.
- Trial name
- NCT00627016
- Testing
- Dexlansoprazole
- Where
- 43 sites in United States
- Volunteers
- 305 people
- Sponsor
- Takeda
Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History
The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in symptomatic patients with moderate to very severe COPD who are receiving standard of care therapies
- Trial name
- GALATHEA (NCT02138916)
- Testing
- Benralizumab Arm A, Benralizumab Arm B
- Where
- 407 sites in United States, Austria and 15 more
- Volunteers
- 1,656 people
- Sponsor
- AstraZeneca
Clostridium Difficile
SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)
The study will involve administering the study drug as a single dose of study drug or placebo. This study is designed to demonstrate the superiority of the experimental drug versus placebo in adult patients with recurrent CDI.
- Trial name
- ECOSPOR (NCT02437487)
- Testing
- SER-109
- Where
- 30 sites in United States
- Volunteers
- 89 people
- Sponsor
- Seres Therapeutics, Inc.
Rheumatoid Arthritis
Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers
Primary Objective: To demonstrate that sarilumab (SAR153191/REGN88) on top of methotrexate (MTX) was superior in efficacy to placebo for the relief of signs and symptoms of rheumatoid arthritis (RA), in participants with active…
- Trial name
- NCT01217814
- Testing
- Sarilumab, Golimumab, methotrexate (MTX)
- Where
- 14 sites in United States, Colombia and 4 more
- Volunteers
- 16 people
- Sponsor
- Sanofi
Chronic Constipation, Constipation
Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating
The purpose of this study is to evaluate the efficacy and safety of linaclotide compared with placebo in patients with chronic constipation (CC) and prominent abdominal bloating.
- Trial name
- NCT01642914
- Testing
- Linaclotide 290 micrograms, Linaclotide 145 micrograms
- Where
- 151 sites in United States, Canada
- Volunteers
- 487 people, healthy volunteers welcome
- Sponsor
- Forest Laboratories
Ulcerative Colitis
A Pilot Study of GWP42003 in the Symptomatic Treatment of Ulcerative Colitis (GWID10160)
This study was conducted to determine the efficacy and safety of GWP42003 compared with placebo by the percentage of participants achieving remission quantified as a Mayo score of 2 or less (with no sub-score >1) after 10 weeks…
- Trial name
- NCT01562314
- Testing
- GWP42003
- Where
- 8 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- GW Research Ltd
Diabetic Foot Ulcer of Neuropathic Origin
The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Southern Europe The TRANS-South Study
Trafermin is a recombinant human basic fibroblast growth factor (bFGF; original development code, KCB-1), which is manufactured by genetic engineering using Escherichia coli by Kaken Pharmaceutical Co., Ltd. (Tokyo, Japan).
- Trial name
- TRANS-South (NCT01217463)
- Testing
- Trafermin 0.01% spray
- Where
- 24 sites in Czechia, France and 2 more
- Volunteers
- 201 people
- Sponsor
- Olympus Biotech Corporation
Psoriatic Arthritis
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis who have not been previously treated with DMARDs.
- Trial name
- PALACE4 (NCT01307423)
- Testing
- Apremilast 20mg, Apremilast 30mg
- Where
- 118 sites in United States, Australia and 16 more
- Volunteers
- 529 people
- Sponsor
- Amgen
Narcolepsy
A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Without Cataplexy
This study is of an investigational drug called SUVN-G3031 (Samelisant) as a possible treatment for narcolepsy with cataplexy or narcolepsy without cataplexy.
- Trial name
- SUVN-G3031 (NCT04072380)
- Testing
- SUVN-G3031
- Where
- 41 sites in United States, Canada
- Volunteers
- 190 people
- Sponsor
- Suven Life Sciences Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.